Literature DB >> 15525847

Late-onset systemic lupus erythematosus: a personal series of 47 patients and pooled analysis of 714 cases in the literature.

Jacques Boddaert1, Du Le Thi Huong, Zahir Amoura, Bertrand Wechsler, Pierre Godeau, Jean-Charles Piette.   

Abstract

Systemic lupus erythematosus (SLE) is uncommon after the age of 50 years, and studies of elderly patients with SLE are scarce. We conducted the current study to analyze characteristics and outcome of patients with late-onset SLE in a French tertiary referral center, and to compare them with those of younger patients with SLE. From 1980 to 2000, 47 patients were identified as having late-onset SLE, defined as SLE diagnosed at or over the age of 50 years. These patients were compared with a group of 114 randomly selected patients aged younger than 50 years at SLE diagnosis. We compared clinical characteristics, laboratory data, therapy, and course. The female to male ratio was smaller in the late-onset SLE group (p = 0.0012). Some manifestations occurred less frequently in late-onset SLE: arthritis (p = 0.009), malar rash (p = 0.013), and nephropathy (p = 0.009). High-dose corticosteroids (p = 0.0016) and immunosuppressive drugs (p = 0.006) were less commonly used in the elderly. Deaths occurred more frequently in late-onset SLE (p = 0.019), with a 10-year survival rate of 71% versus 95% in early-onset SLE (p < 0.01). In patients with late-onset SLE, causes of death were usually unrelated to SLE. Analysis of pooled data from the literature, based on 714 old and 4700 young SLE patients, confirmed that late-onset SLE was characterized by a smaller female to male ratio (4.4:1 vs. 10.6:1; p = 3.10); a higher occurrence of serositis (36.7% vs. 28.6%; p = 7.10) and pulmonary involvement (21.2% vs. 11.3%; p = 6.10); and a lower occurrence of malar rash (31.1% vs. 62.4%; p = 10), photosensitivity (26.2% vs. 38.2%; p = 6.10), purpura/cutaneous vasculitis (13.4% vs. 25.9%; p = 9.10), alopecia/hair loss (24% vs. 44.9%; p = 3.10), Raynaud phenomenon (24.8% vs. 37.2%; p = 3.10), neuropsychiatric manifestations (15.3% vs. 20.2%; p = 0.025), lymphadenopathy (9.1% vs. 19.6%; p = 2.10), nephrotic syndrome (8.1% vs. 24.3%; p = 0.015), and nephritis (28.6% vs. 42.7%; p = 2.10). Regarding laboratory features, rheumatoid factor positivity was more frequent (32.7% vs. 20.1%; p = 3.10), whereas anti-RNP positivity (10.4% vs. 20.9%; p = 9.10), anti-Sm positivity (9.1% vs. 17.1%; p = 0.001), and a low CH50 complement fraction (45% vs. 64.9%; p = 0.002) were less frequent in old compared with young SLE patients. In conclusion, the clinical pattern of late-onset SLE is characterized by a lower disease severity. The reduced survival observed in this group seems to result mainly from the consequences of aging.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15525847     DOI: 10.1097/01.md.0000147737.57861.7c

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.889


  47 in total

1.  Late onset lupus nephritis: analysis of clinical manifestations and renal pathological features in Chinese patients.

Authors:  Zheng Tang; Dongmei Chen; Shengmei Yang; Haitao Zhang; Weixin Hu; Zhihong Liu; Leishi Li
Journal:  Rheumatol Int       Date:  2010-06-10       Impact factor: 2.631

2.  Environmental exposure, estrogen and two X chromosomes are required for disease development in an epigenetic model of lupus.

Authors:  Faith M Strickland; Anura Hewagama; Qianjian Lu; Ailing Wu; Robert Hinderer; Ryan Webb; Kent Johnson; Amr H Sawalha; Colin Delaney; Raymond Yung; Bruce C Richardson
Journal:  J Autoimmun       Date:  2011-12-03       Impact factor: 7.094

Review 3.  Late-onset systemic lupus erythematosus: epidemiology, diagnosis and treatment.

Authors:  Laurent Arnaud; Alexis Mathian; Jacques Boddaert; Zahir Amoura
Journal:  Drugs Aging       Date:  2012-03-01       Impact factor: 3.923

Review 4.  Giant cell arteritis and polymyalgia rheumatica: pathophysiology and management.

Authors:  Miguel A Gonzalez-Gay; Carlos Garcia-Porrua; Jose A Miranda-Filloy; Javier Martin
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

Review 5.  Elderly-onset systemic lupus erythematosus: prevalence, clinical course and treatment.

Authors:  Deana Lazaro
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

Review 6.  The impact of anti-U1-RNP positivity: systemic lupus erythematosus versus mixed connective tissue disease.

Authors:  Alina Dima; Ciprian Jurcut; Cristian Baicus
Journal:  Rheumatol Int       Date:  2018-05-23       Impact factor: 2.631

7.  Less disease severity and favorable prognosis are associated with postmenopausal systemic lupus erythematosus patients.

Authors:  Xiao Li Deng; Xiang Yuan Liu
Journal:  Rheumatol Int       Date:  2008-09-25       Impact factor: 2.631

8.  Pulmonary manifestations in late versus early systemic lupus erythematosus: A systematic review and meta-analysis.

Authors:  Jennifer L Medlin; Karen E Hansen; Sara S McCoy; Christie M Bartels
Journal:  Semin Arthritis Rheum       Date:  2018-01-31       Impact factor: 5.532

Review 9.  [Skin diseases in geriatric patients. Epidemiologic data].

Authors:  E Makrantonaki; A I Liakou; R Eckardt; M Zens; E Steinhagen-Thiessen; C C Zouboulis
Journal:  Hautarzt       Date:  2012-12       Impact factor: 0.751

Review 10.  Autoimmune diseases and reproductive aging.

Authors:  Riley Bove
Journal:  Clin Immunol       Date:  2013-02-28       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.